IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024, at the New York Athletic Club in New York City.
Dr. Jennifer Bath, President and CEO, will represent IPA at the conference, conducting one-on-one meetings with investors and analysts. The conference provides a unique platform for emerging growth and dynamic publicly traded companies to connect directly with institutional and individual investors.
Interested parties must register for the conference to schedule meetings with Dr. Bath through the conference platform.
ImmunoPrecise Antibodies (IPA), una società di ricerca e tecnologia biotecnologica guidata dall'IA, ha annunciato la sua partecipazione alla 13a Conferenza Annuale Discovery One-on-One della Benchmark Company. L'evento si svolgerà il 11 dicembre 2024, presso il New York Athletic Club a New York.
La Dr.ssa Jennifer Bath, Presidente e CEO, rappresenterà l'IPA durante la conferenza, conducendo incontri individuali con investitori e analisti. La conferenza offre una piattaforma unica per le aziende pubbliche in crescita e dinamiche per connettersi direttamente con investitori istituzionali e individuali.
Le parti interessate devono registrarsi per la conferenza per pianificare incontri con la Dr.ssa Bath tramite la piattaforma dell'evento.
ImmunoPrecise Antibodies (IPA), una empresa de investigación y tecnología bioterapéutica impulsada por IA, ha anunciado su participación en la 13.ª Conferencia Anual de Inversores Discovery One-on-One de la Benchmark Company. El evento se llevará a cabo el 11 de diciembre de 2024, en el New York Athletic Club en la ciudad de Nueva York.
La Dra. Jennifer Bath, Presidenta y CEO, representará a IPA en la conferencia, realizando reuniones individuales con inversores y analistas. La conferencia ofrece una plataforma única para que las empresas públicas en crecimiento y dinámicas se conecten directamente con inversores institucionales e individuales.
Las partes interesadas deben registrarse para la conferencia a fin de programar reuniones con la Dra. Bath a través de la plataforma de la conferencia.
ImmunoPrecise Antibodies (IPA), 인공지능 기반의 생물 의약품 연구 및 기술 회사, 벤치마크 회사의 제13회 연례 Discovery One-on-One 투자자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 12월 11일 뉴욕시의 뉴욕 체육관에서 열릴 예정입니다.
제니퍼 배스 박사, 사장 겸 CEO가 회의에서 IPA를 대표하며, 투자자 및 분석가와의 일대일 미팅을 진행할 것입니다. 이번 회의는 성장 잠재력이 있는 공개 상장 회사들이 기관 및 개인 투자자와 직접 연결될 수 있는 독특한 플랫폼을 제공합니다.
관심 있는 당사자는 회의 플랫폼을 통해 배스 박사와의 미팅을 일정을 예약하기 위해 회의에 등록해야 합니다.
ImmunoPrecise Antibodies (IPA), une entreprise de recherche et technologie biothérapeutique alimentée par l'IA, a annoncé sa participation à la 13e Conférence Annuelle Discovery One-on-One de la Benchmark Company. L'événement aura lieu le 11 décembre 2024, au New York Athletic Club à New York.
Dr. Jennifer Bath, Présidente et CEO, représentera IPA lors de la conférence, menant des réunions individuelles avec des investisseurs et des analystes. La conférence offre une plateforme unique pour les entreprises dynamiques et en pleine croissance cotées en bourse afin de se connecter directement avec des investisseurs institutionnels et individuels.
Les parties intéressées doivent s'inscrire à la conférence pour planifier des réunions avec Dr. Bath via la plateforme de la conférence.
ImmunoPrecise Antibodies (IPA), ein KI-gestütztes Unternehmen für biotherapeutische Forschung und Technologie, hat seine Teilnahme an der 13. Jahreskonferenz Discovery One-on-One der Benchmark Company bekannt gegeben. Die Veranstaltung findet am 11. Dezember 2024 im New York Athletic Club in New York City statt.
Dr. Jennifer Bath, Präsidentin und CEO, wird IPA auf der Konferenz repräsentieren und One-on-One-Meetings mit Investoren und Analysten durchführen. Die Konferenz bietet eine einzigartige Plattform für wachstumsstarke und dynamische börsennotierte Unternehmen, um direkt mit institutionellen und privaten Investoren in Kontakt zu treten.
Interessierte Parteien müssen sich für die Konferenz registrieren, um Meetings mit Dr. Bath über die Konferenzplattform zu planen.
- None.
- None.
The conference offers emerging growth, and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format. During the event, Dr. Jennifer Bath, President and CEO, will be participating in one-on-one meetings with investors and analysts throughout the day. To schedule a one-on-one meeting with Dr. Jennifer Bath, please first register here for the conference. Once you are registered, you'll gain access to the platform to submit your meeting request.
About The Benchmark Company
The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges. IPA has several subsidiaries in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204494793/en/
Investor Relations Contact
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
When is IPA (NASDAQ: IPA) presenting at The Benchmark Company's Discovery Conference?
What type of meetings will IPA conduct at the Benchmark Discovery Conference 2024?
How can investors schedule meetings with IPA at the Benchmark Conference 2024?
Where will the Benchmark Discovery Conference featuring IPA take place?
